Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Business Wire•06/08/2026•07:00 ET
0
Whiz Insights
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
* Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date
Get started
Create a free account to read the full story.